Genome Editing of HBG1 and HBG2 to Induce Fetal Hemoglobin

Jean-Yves Metais,Phillip A. Doerfler,Thiyagaraj Mayuranathan,Daniel E. Bauer,Stephanie C. Fowler,Matthew M. Hsieh,Varun Katta,Sagar Keriwala,Cicera R. Lazzarotto,Kevin Luk,Michael D. Neel,S. Scott Perry,Samuel T. Peters,Shaina N. Porter,Byoung Y. Ryu,Akshay Sharma,Devlin Shea,John F. Tisdale,Naoya Uchida,Scot A. Wolfe,Kaitly J. Woodard,Yuxuan Wu,Yu Yao,Jing Zeng,Shondra Pruett-Miller,Shengdar Q. Tsai,Mitchell J. Weiss

DOI: https://doi.org/10.1182/bloodadvances.2019000820

IF: 7.642

2019-01-01

Blood Advances

Abstract:Key Points Cas9 editing of the γ-globin gene promoters in hematopoietic stem cells (HSCs) increases red cell HbF by ≤40%. No deleterious effects on hematopoiesis or off-target mutations were detected 16 weeks after xenotransplantation of edited HSCs.